<DOC>
	<DOCNO>NCT00577161</DOCNO>
	<brief_summary>BBR 2778 novel aza-anthracenedione activity experimental tumor reduce delayed cardiotoxicity animal model compare reference standard . This cytotoxic agent structural similarity mitoxantrone well general similarity anthracyclines ( tricyclic central quinoid chromophore7 ) . This phase III study compare efficacy safety combination BBR 2778 , fludarabine , rituximab combination fludarabine rituximab patient relapse refractory indolent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Fludarabine , Pixantrone Rituximab v Fludarabine Rituximab forRelapsed Refractory Indolent NHL</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion Criteria 1 . Histologically confirm relapsed refractory indolent nonHodgkin 's lymphoma ( NHL ) 2 . Any stage ( Ann Arbor staging , Appendix 15.7 ) , without B symptom 3 . CD 20+ lymphoma ( confirmed immunochemistry ) 4 . Measurable disease . 5 . Atleast 1 prior therapy . 6 . Age ≥ 18 year 7 . Life expectancy least 3 month 8 . ECOG performance status ( PS ) 0 1 9 . Adequate cardiac function define LVEF ≥ 50 % MUGA scan 10 . Adequate renal function 11 . Adequate hepatic function 12 . Adequate bone marrow function 13 . Recovery acute toxicity prior therapy ( except alopecia grade 1 peripheral neuropathy ) . Exclusion Criteria 1 . Prior treatment cumulative dose doxorubicin equivalent exceed 450 mg/m2 2 . Radiotherapy , chemotherapy therapy NHL within 4 week treatment start 3 . Systemic corticosteroid treat NHL within 5 day prior first dose study treatment . 4 . Radioimmunotherapy ( RIT ) within 3 month treatment start 5 . Known hypersensitivity excipients study drug patient receive 6 . Known Type I hypersensitivity anaphylactic reaction murine protein component rituximab 7 . Major thoracic and/or abdominal surgery precede 4 week , patient fully recover ( patient minor surgery one week 's recovery period may enrol ) 8 . HIVrelated lymphoma 9 . Active CNS involvement 10 . Clinically significant cardiovascular abnormality 11 . Serious ( NCI CTCAE grade 34 ) intercurrent infection randomization , infection require oral antibiotic , deepseated systemic mycotic infection . 12 . Investigational study drug within 30 day randomization . Patient must recover side effect investigational therapy . 13 . Clinical symptom suggest unresolved HIV , HBV HCV infection . . 14 . History another malignancy except : curatively treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently remission , cancer patient diseasefree 5 year 15 . Pregnant lactate woman 16 . Potentially fertile men woman sexual partner willing use adequate contraception define Investigator study 6 month last day study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>pixantrone</keyword>
	<keyword>NHL</keyword>
	<keyword>rituximab</keyword>
	<keyword>fludarabine</keyword>
</DOC>